Here's a great opportunity to participate in an advanced prostate cancer marketing survey, earn $40 dollars for yourself and help move our understanding of our disease just a little bit further forward. What is the purpose? Understanding patients' knowledge and perceptions of treatments for prostate cancer, so researchers can understand how prostate cancer affects patients [...]
I have heard some occasional discussion that once (that is if) enzalutamide (MDV-3100) is approved by the FDA for the treatment of men with advanced prostate cancer, it will over shadow Provenge. On the contrary, I believe that the approval of enzalutamide will actually encourage additional use of Provenge resulting in the increasing use of [...]
Advanced registered nurse practitioners (ARNP) had been integrated into the oncology team at the Mayo Clinic in Jacksonville, Florida with the purpose of discussing palliative care intervention for persons newly diagnosed with metastatic cancer. The team found that this type of intervention improved emotional and mental quality of life (QoL) for those patients who participated [...]
Yesterday, Johnson & Johnson announced that it has asked U.S. and European Union regulators to grant broader marketing approval for its cancer pill, Zytiga which is used to treat men with castrate resistant prostate cancer. Zytiga was approved in 2011 for the treatment of advanced prostate cancer in men who have received chemotherapy and who [...]
Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases using Alpharadin, compared to the interim analysis from June 2011. • Overall survival in Alpharadin arm increased by 44% • [...]